A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Non-Small Cell Lung Cancer|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Hepatocellular Carcinoma|Castration-resistant Prostate Cancer|Ovarian Cancer
DRUG: Nanrilkefusp Alfa|DRUG: Pembrolizumab
Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), Day 1 up to approximately 3 years
Number of Participants with a Treatment-emergent Adverse Event (TEAE), Day 1 up to approximately 3 years|Number of Participants with an Adverse Event of Special Interest (AESI), Day 1 up to approximately 3 years|Immune ORR (iORR) According to RECIST for immune-based therapeutics (iRECIST), Day 1 up to approximately 3 years|Best Overall Response (BOR) According to RECIST 1.1, Day 1 up to approximately 3 years|Immune BOR (iBOR) According to iRECIST, Day 1 up to approximately 3 years|Duration of Response (DoR) According to RECIST 1.1, Day 1 up to approximately 3 years|Immune DoR (iDoR) According to iRECIST, Day 1 up to approximately 3 years|Clinical Benefit Rate (CBR) According to RECIST 1.1, Day 1 up to approximately 3 years|Immune CBR (iCBR) According to iRECIST, Day 1 up to approximately 3 years|Progression-free Survival (PFS) According to RECIST 1.1, Day 1 up to approximately 3 years|Immune PFS (iPFS) According to iRECIST, Day 1 up to approximately 3 years|Time to Response (TtR) According to RECIST 1.1, Day 1 up to approximately 3 years|Immune TtR (iTtR) According to iRECIST, Day 1 up to approximately 3 years|Metastatic Castration-resistant Prostate Cancer (mCRPC) only: DoR as Assessed According to Prostate Cancer Clinical Trials Working Group 3 (PCWG3)-modified RECIST 1.1, Day 1 up to approximately 3 years|mCRPC only: CBR as Assessed According to PCWG3-modified RECIST 1.1, Day 1 up to approximately 3 years|mCRPC only: PFS as Assessed According to PCWG3-modified RECIST 1.1, Day 1 up to approximately 3 years|mCRPC only: Circulating Tumor Cell (CTC) Count Conversion as Assessed According to PCWG3-modified RECIST 1.1, Day 1 up to approximately 2 years|mCRPC only: Confirmed Prostate-specific Antigen (PSA) Decline of â‰¥50% as Assessed According to PCWG3-modified RECIST 1.1, Day 1 up to approximately 2 years|mCRPC only: Time to Confirmed PSA Progression as Assessed According to PCWG3-modified RECIST 1.1, Day 1 up to approximately 2 years|Nanrilkefusp Alfa Concentration Profile at Various Timepoints, Cycle 1 Day 1 to Cycle 3 Day 1 (up to approximately 9 weeks, where each cycle is 3 weeks)|Number of Participants with Anti-drug Antibodies (ADAs), Day 1 up to approximately 2 years
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.